NASDAQ:HARP Harpoon Therapeutics - HARP Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Harpoon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.69 +0.03 (+4.54%) (As of 03/30/2023 12:00 AM ET) Add Compare Share Share Today's Range$0.66▼$0.7050-Day Range$0.65▼$1.3752-Week Range$0.59▼$5.16Volume332,750 shsAverage Volume464,219 shsMarket Capitalization$22.87 millionP/E RatioN/ADividend YieldN/APrice Target$7.61 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Harpoon Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.78 Rating ScoreUpside/Downside961.7% Upside$7.33 Price TargetShort InterestHealthy2.02% of Float Sold ShortDividend StrengthN/ASustainability-0.61Upright™ Environmental ScoreNews Sentiment-0.01Based on 10 Articles This WeekInsider TradingAcquiring Shares$10 M Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.74) to ($0.34) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.57 out of 5 starsMedical Sector129th out of 1,009 stocksBiological Products, Except Diagnostic Industry21st out of 166 stocks 3.4 Analyst's Opinion Consensus RatingHarpoon Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.78, and is based on 7 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.33, Harpoon Therapeutics has a forecasted upside of 961.7% from its current price of $0.69.Amount of Analyst CoverageHarpoon Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.02% of the float of Harpoon Therapeutics has been sold short.Short Interest Ratio / Days to CoverHarpoon Therapeutics has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Harpoon Therapeutics has recently increased by 60.60%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldHarpoon Therapeutics does not currently pay a dividend.Dividend GrowthHarpoon Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreHarpoon Therapeutics has received a 76.34% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for cancer", "Preclinical research services for physical health", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Harpoon Therapeutics is -0.61. Previous Next 1.1 News and Social Media Coverage News SentimentHarpoon Therapeutics has a news sentiment score of -0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Harpoon Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 8 people have searched for HARP on MarketBeat in the last 30 days. This is a decrease of -71% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Harpoon Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Harpoon Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $10,000,000.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders13.00% of the stock of Harpoon Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions65.52% of the stock of Harpoon Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Harpoon Therapeutics are expected to grow in the coming year, from ($0.74) to ($0.34) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Harpoon Therapeutics is -0.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Harpoon Therapeutics is -0.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHarpoon Therapeutics has a P/B Ratio of 0.39. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Harpoon Therapeutics (NASDAQ:HARP) StockHarpoon Therapeutics Inc. is a clinical-stage immunotherapy company at the forefront of revolutionizing cancer treatment and other diseases. The company is developing a novel T-cell engagers class to use the body's immune system to fight infection. Harpoon currently has several products in various stages of clinical trials, such as HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors and HPN217, which is in Phase I/II clinical trials for the treatment of multiple myeloma. Shares of Harpoon have skyrocketed following the release of data from its Phase 1 clinical trial for HPN217, a single-agent candidate for pretreated patients with relapsed/refractory multiple myeloma (RRMM). The data showed clinical activity and a "tolerable safety profile," with low-grade CRS observed in 29% of patients following the first or second doses of the drug and no incidents of "Grade 3 or higher CRS." Analysts have a consensus price target of $8.75 on the stock, suggesting over 85% upside potential. Harpoon has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products incorporating TriTAC platform technology and soluble T cell receptors. In addition, the company has a preclinical stage product, HPN601, for treating multiple solid tumor indications.Read More Receive HARP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Harpoon Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address HARP Stock News HeadlinesMarch 30, 2023 | americanbankingnews.comHarpoon Therapeutics, Inc. (NASDAQ:HARP) Director Acquires $10,000,000.00 in StockMarch 29, 2023 | finance.yahoo.comHarpoon Therapeutics Full Year 2022 Earnings: Misses ExpectationsMarch 30, 2023 | WealthPop (Ad)Here’s Your Own Billion-Dollar Trading Edge (Just $0.76 a Week)2023 is a classic “stock picker’s market.” The only way to beat these markets is to pick the right stocks at the right time. Legendary trader Adam Mesh is ready to hand you his best stock pick every week… It’s the same kind of research Wall Street’s top traders use to beat the markets. Click here to get his three top picks for right now to help get you started now. March 29, 2023 | americanbankingnews.comHarpoon Therapeutics (NASDAQ:HARP) Releases Quarterly Earnings ResultsMarch 27, 2023 | msn.comInterpace Biosciences GAAP EPS of -$0.33, revenue of $8.33MMarch 14, 2023 | finance.yahoo.comHarpoon Therapeutics Announces Acceptance of Five Abstracts for Presentation at AACR Annual Meeting 2023February 24, 2023 | seekingalpha.comHARP Harpoon Therapeutics, Inc.February 13, 2023 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Tenet Healthcare (THC), Replimune Group (REPL) and Immunic (IMUX)March 30, 2023 | Weiss Ratings (Ad)Fed's Shocking New Plan to Control Your MoneyThe Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. February 7, 2023 | msn.comSeagen vets land $4.4M for Univ. of Washington spinout using fresh approach for cancer vaccinesFebruary 7, 2023 | finance.yahoo.comHarpoon Therapeutics to Participate in the SVB Securities Global Biopharma ConferenceJanuary 25, 2023 | finance.yahoo.comWhy Fast-paced Mover Harpoon Therapeutics, Inc. (HARP) Is a Great Choice for Value InvestorsJanuary 18, 2023 | forbes.comHarpoon TherapeuticsDecember 27, 2022 | msn.comHarpoon Therapeutics Earnings Perspective: Return On Capital EmployedDecember 13, 2022 | benzinga.comShort Volatility Alert: Harpoon TherapeuticsDecember 13, 2022 | msn.comLooking Into Harpoon Therapeutics's Recent Short InterestDecember 12, 2022 | msn.comHarpoon adds 122% on updated Phase 1 data for multiple myeloma therapyDecember 5, 2022 | finance.yahoo.comHarpoon Therapeutics to Host HPN217 Interim Results and Corporate Update Call and Webcast on December 12, 2022November 30, 2022 | finance.yahoo.comPathios Therapeutics Appoints Jeanmarie Guenot, Ph.D., as Non-Executive DirectorNovember 21, 2022 | finance.yahoo.comHarpoon Therapeutics to Participate in the Piper Sandler 34th Annual Healthcare ConferenceNovember 21, 2022 | finance.yahoo.comHarpoon Therapeutics to Participate in the Piper Sandler 34th Annual Healthcare ConferenceNovember 19, 2022 | finance.yahoo.comAnalysts Just Published A Bright New Outlook For Harpoon Therapeutics, Inc.'s (NASDAQ:HARP)November 15, 2022 | finance.yahoo.comHarpoon Therapeutics Updates Strategic Priorities and Reports Third Quarter 2022 Financial ResultsNovember 15, 2022 | finance.yahoo.comHarpoon Therapeutics, Inc. (HARP) Reports Q3 Loss, Tops Revenue EstimatesNovember 3, 2022 | finance.yahoo.comHarpoon Therapeutics to Present Interim Results from Phase 1 Clinical Trial of T Cell Engager HPN217 at the 64th ASH Annual Meeting and ExpositionOctober 6, 2022 | seekingalpha.comHarpoon Therapeutics appoints Luke Walker as CMOOctober 4, 2022 | finance.yahoo.comHarpoon Therapeutics Appoints Luke Walker, M.D., as Chief Medical OfficerSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive HARP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Harpoon Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address HARP Company Calendar Last Earnings3/27/2023Today3/30/2023Next Earnings (Estimated)5/11/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:HARP CUSIPN/A CIK1708493 Webwww.harpoontx.com Phone(650) 443-7400FaxN/AEmployees99Year FoundedN/APrice Target and Rating Average Stock Price Forecast$7.33 High Stock Price Forecast$18.00 Low Stock Price Forecast$1.50 Forecasted Upside/Downside+1,001.9%Consensus RatingModerate Buy Rating Score (0-4)2.78 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($2.05) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-116,720,000.00 Net Margins-212.23% Pretax Margin-220.41% Return on Equity-239.23% Return on Assets-62.54% Debt Debt-to-Equity RatioN/A Current Ratio1.28 Quick Ratio1.28 Sales & Book Value Annual Sales$31.92 million Price / Sales0.72 Cash FlowN/A Price / Cash FlowN/A Book Value$1.77 per share Price / Book0.39Miscellaneous Outstanding Shares33,110,000Free Float28,803,000Market Cap$22.87 million OptionableNot Optionable Beta1.57 Key ExecutivesJulia Marie EastlandPresident, Chief Executive Officer & DirectorFrank J. LanzaChief Financial & Accounting OfficerHolger WescheChief Scientific OfficerLuke N. WalkerChief Medical OfficerRachael LesterSVP-Business Development & Corporate StrategyKey CompetitorsAziyo BiologicsNASDAQ:AZYOSurrozenNASDAQ:SRZNSAB BiotherapeuticsNASDAQ:SABSGenetic TechnologiesNASDAQ:GENEAIM ImmunoTechNYSE:AIMView All CompetitorsInsiders & InstitutionsRonald HuntBought 10,000 shares on 3/23/2023Total: $10 M ($1,000.00/share)Millennium Management LLCBought 555,117 shares on 2/15/2023Ownership: 3.734%Renaissance Technologies LLCSold 148,067 shares on 2/13/2023Ownership: 1.006%Levin Capital Strategies L.P.Bought 330,000 shares on 2/13/2023Ownership: 0.997%Geode Capital Management LLCSold 12,303 shares on 2/13/2023Ownership: 0.654%View All Insider TransactionsView All Institutional Transactions HARP Stock - Frequently Asked Questions Should I buy or sell Harpoon Therapeutics stock right now? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Harpoon Therapeutics in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" HARP shares. View HARP analyst ratings or view top-rated stocks. What is Harpoon Therapeutics' stock price forecast for 2023? 9 equities research analysts have issued 1-year target prices for Harpoon Therapeutics' shares. Their HARP share price forecasts range from $1.50 to $18.00. On average, they predict the company's share price to reach $7.33 in the next twelve months. This suggests a possible upside of 961.7% from the stock's current price. View analysts price targets for HARP or view top-rated stocks among Wall Street analysts. How have HARP shares performed in 2023? Harpoon Therapeutics' stock was trading at $0.7257 at the beginning of the year. Since then, HARP stock has decreased by 4.8% and is now trading at $0.6907. View the best growth stocks for 2023 here. Are investors shorting Harpoon Therapeutics? Harpoon Therapeutics saw a increase in short interest in March. As of March 15th, there was short interest totaling 387,700 shares, an increase of 60.6% from the February 28th total of 241,400 shares. Based on an average daily trading volume, of 498,900 shares, the short-interest ratio is presently 0.8 days. Approximately 2.0% of the shares of the stock are short sold. View Harpoon Therapeutics' Short Interest. When is Harpoon Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 11th 2023. View our HARP earnings forecast. How were Harpoon Therapeutics' earnings last quarter? Harpoon Therapeutics, Inc. (NASDAQ:HARP) released its earnings results on Monday, March, 27th. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.47) by $0.08. The business earned $4.09 million during the quarter, compared to the consensus estimate of $11.06 million. Harpoon Therapeutics had a negative trailing twelve-month return on equity of 239.23% and a negative net margin of 212.23%. What is Gerald McMahon's approval rating as Harpoon Therapeutics' CEO? 5 employees have rated Harpoon Therapeutics Chief Executive Officer Gerald McMahon on Glassdoor.com. Gerald McMahon has an approval rating of 100% among the company's employees. This puts Gerald McMahon in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 100.0% of employees surveyed would recommend working at Harpoon Therapeutics to a friend. What other stocks do shareholders of Harpoon Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Harpoon Therapeutics investors own include Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), Alector (ALEC), Precision BioSciences (DTIL), Editas Medicine (EDIT), Gossamer Bio (GOSS), Kaleido Biosciences (KLDO), NVIDIA (NVDA), Ovid Therapeutics (OVID) and Advanced Micro Devices (AMD). When did Harpoon Therapeutics IPO? (HARP) raised $76 million in an initial public offering (IPO) on Friday, February 8th 2019. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. Citigroup and Leerink Partners served as the underwriters for the IPO and Canaccord Genuity and Wedbush PacGrow were co-managers. What is Harpoon Therapeutics' stock symbol? Harpoon Therapeutics trades on the NASDAQ under the ticker symbol "HARP." Who are Harpoon Therapeutics' major shareholders? Harpoon Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Millennium Management LLC (3.73%), Renaissance Technologies LLC (1.01%), Levin Capital Strategies L.P. (1.00%), Geode Capital Management LLC (0.65%), Sequoia Financial Advisors LLC (0.18%) and Cutler Group LLC CA (0.00%). Insiders that own company stock include Ansbert Gadicke, Bioscience Plc Arix, Bioventures 2014 LP Mpm, Georgia Erbez, Holger Wesche, Impact Fund (Cayman) Oncology, Natalie Sacks and Ronald Hunt. View institutional ownership trends. How do I buy shares of Harpoon Therapeutics? Shares of HARP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Harpoon Therapeutics' stock price today? One share of HARP stock can currently be purchased for approximately $0.69. How much money does Harpoon Therapeutics make? Harpoon Therapeutics (NASDAQ:HARP) has a market capitalization of $22.87 million and generates $31.92 million in revenue each year. The company earns $-116,720,000.00 in net income (profit) each year or ($2.05) on an earnings per share basis. How can I contact Harpoon Therapeutics? Harpoon Therapeutics' mailing address is 131 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.harpoontx.com. The company can be reached via phone at (650) 443-7400 or via email at ir@harpoontx.com. This page (NASDAQ:HARP) was last updated on 3/30/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.